Table 1. Characteristics of patients with and without adverse cardiac events#.
| Variables | All patients | Patients without adverse cardiac events | Patients with adverse cardiac events | p-value* |
|---|---|---|---|---|
| (n = 143) | (n = 113) | (n = 30) | ||
| Age at follow-up (years) | 27.5 ± 12.0 | 26.5 ± 10.8 | 31.1 ± 15.5 | ns |
| Number of patients with Fontan palliation or Eisenmenger physiology | 59/143 (41%) | 41/113 (36.3%) | 18/30 (60%) | 0.02 |
| NYHA functional class | 1.6 ± 0.7 | 1.4 ± 0.5 | 2.3 ± 0.9 | < 0.001 |
| Systolic blood pressure (mmHg) | 121.4 ± 14.7 | 121.9 ± 13.6 | 119.9 ± 18.3 | ns |
| Diastolic blood pressure (mmHg) | 70.8 ± 9.2 | 71.2 ± 9.2 | 69.1 ± 9.2 | ns |
| Transcutaneous oxygen saturation at rest (%) | 94.5 ± 5.8 | 95.5 ± 4.4 | 90.5 ± 8.4 | < 0.001 |
| Ejection fraction of SV (%) | 50.9 ± 11.3 | 53.0 ± 9.2 | 43.0 ± 14.9 | < 0.001 |
| Enddiastolic volume of SV (ml) | 110.0 ± 43.7 | 106.3 ± 39.9 | 123.8 ± 54.4 | ns |
| Endsystolic volume of SV (ml) | 55.8 ± 32.0 | 50.9 ± 24.4 | 74.3 ± 47.6 | 0.004 |
| VTI above aortic valve (cm) | 24.0 ± 5.0 | 24.7 ± 4.5 | 21.4 ± 5.9 | 0.004 |
| Creatinine (mg/dl) | 0.81 | 0.80 | 0.84 | ns |
| (0.70–0.95) | (0.70–0.94) | (0.59–1.1) | ||
| Estimated GFR (ml/min) | 102.1 | 103.4 | 96.3 | ns |
| (90.4–118.9) | (92.6–119.6) | (82.7–118.3) | ||
| γGT (U/l) | 41.0 | 34.0 | 72.0 | < 0.001 |
| (24.0–71.0) | (22.0–61.0) | (55.5–102.3) | ||
| Albumin (g/l) | 47.0 | 47.0 | 45.0 | 0.034 |
| (44.0–49.0) | (45.0–49.0) | (40.8–50.0) | ||
| NT-proBNP (pg/ml) | 164.7 | 136.7 | 651.0 | < 0.001 |
| (77.4–501.1) | (68.9–275.8) | (275.1–1326.2) | ||
| Homoarginine (μmol/l) | 1.5 | 1.63 | 1.03 | < 0.001 |
| (1.12–1.98) | (1.28–2.12) | (0.78–1.36) |
CHD, congenital heart disease; NYHA, New York Heart Association; SV, systemic ventricle; VTI, velocity time integral; GFR, glomerular filtration rate
# Mean ± standard deviation or median (interquartile range) are used
* Patients with compared to those without adverse cardiac events